Market Potential for NovaTarg Lead Compounds
NT1195 for T2D patients with Kidney Disease
The global Type 2 Diabetes (T2D) market was $31.2 billion in 2015. The segment of the T2D market targeted by NT1195 (T2D patients that cannot benefit from metformin) has a current value of ~$6-8 billion.
NovaTarg is the first company to discover and develop a drug for this patient group and, if approved, NT1195 will be a blockbuster by 2026.
NT1195 for Endometrial Cancer
In 2014, 710,228 women in the US had endometrial cancer (EC) and in 2017 61,380 new cases of EC were diagnosed. While 5 year survival rates remain high (81.3%), more the 10,000 American women die every year from the disease. Importantly, obese women with EC have a 6.25-fold greater risk of dying from the disease.
The close association of EC with metabolic disease suggests that drugs which target EC in women with insulin resistance have a critical role to play in drug treatment – NT1195 is a novel biguanide designed to treat this most at risk population.
It has been estimated that the global market for drugs to treat EC will reach $27 billion by 2027.
Our Exit Strategy
We plan to complete IND-enabling studies, file an IND for use of NT1195 for the treatment of EC and T2D. $2million will be required to complete the IND submission and conduct of Phase 0 studies of NT1195 for pre-surgical treatment of EC in women with insulin resistance.
A further $3million will be required to complete Phase 1 clinical studies for the treatment of T2D in patients with kidney disease. Sufficient data on safety, tolerability, PK and efficacy will be collected to a make firm decision on progression to Phase 2.
For both EC and T2D, NovaTarg intends to take NT1195 through clinical ‘Proof of Concept’ and plan to out-license following Phase 1/2a……returning benefits to shareholders, as well as future discovery and development projects.